Geode Capital Management LLC Acquires 7,147 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Geode Capital Management LLC boosted its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 0.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 943,344 shares of the company's stock after purchasing an additional 7,147 shares during the quarter. Geode Capital Management LLC owned about 1.96% of Mirum Pharmaceuticals worth $39,016,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Clearbridge Investments LLC increased its position in Mirum Pharmaceuticals by 2.0% in the 4th quarter. Clearbridge Investments LLC now owns 907,317 shares of the company's stock valued at $37,518,000 after buying an additional 18,217 shares in the last quarter. Loomis Sayles & Co. L P raised its position in shares of Mirum Pharmaceuticals by 15.8% during the fourth quarter. Loomis Sayles & Co. L P now owns 578,024 shares of the company's stock worth $23,901,000 after purchasing an additional 78,708 shares during the period. Congress Wealth Management LLC DE acquired a new stake in Mirum Pharmaceuticals in the 4th quarter valued at $414,000. KLP Kapitalforvaltning AS bought a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $277,000. Finally, Teacher Retirement System of Texas lifted its stake in shares of Mirum Pharmaceuticals by 19.7% in the fourth quarter. Teacher Retirement System of Texas now owns 10,613 shares of the company's stock valued at $439,000 after buying an additional 1,748 shares in the last quarter.

Mirum Pharmaceuticals Stock Performance

MIRM stock traded up $0.35 during mid-day trading on Friday, hitting $39.10. The company had a trading volume of 429,075 shares, compared to its average volume of 522,518. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The firm has a market cap of $1.92 billion, a PE ratio of -19.36 and a beta of 1.00. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $54.23. The stock's fifty day moving average price is $45.45 and its two-hundred day moving average price is $43.97.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The firm had revenue of $99.41 million during the quarter, compared to analysts' expectations of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. On average, analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MIRM has been the topic of a number of analyst reports. Robert W. Baird upped their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Thursday, February 27th. HC Wainwright raised their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a report on Friday, February 28th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $58.20.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 902 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $47.92, for a total transaction of $43,223.84. Following the sale, the senior vice president now owns 3,524 shares in the company, valued at $168,870.08. This represents a 20.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total value of $327,629.04. Following the completion of the transaction, the chief executive officer now owns 125,022 shares of the company's stock, valued at approximately $5,991,054.24. This trade represents a 5.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 116,473 shares of company stock valued at $5,249,134. 22.87% of the stock is owned by insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.